Immunic, Inc. announces that the first patients have been enrolled in the Investigator-sponsored Phase 2 clinical trial of IMU-838 in combination with oseltamivir for the treatment of patients with moderate to severe COVID-19. Immunic, Inc. July 27, 2020. Available from www.immunic-therapeutics.com/2020/07/27/immunic-inc-announces-first-patients-enrolled-in-investigator-sponsored-phase-2-clinical-trial-of-imu-838-in-combination-with-oseltamivir-for-the-treatment-of-patients-with-moderate-to-severe-covid-19/. Simpson TF, Kovacs RJ, Plug EC. Risk of ventricular arrhythmia due to treatment with hydroxychloroquine azithromycin for COVID-19. American College of Cardiology; Cardiology magazine. Available from www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. March 29, 2020; Accessed April 1, 2020.
Can-Fite files an application with the U.S. FDA for approval of a new investigational drug for the Phase II covid-19 study. Can-Fite BioPharma July 27, 2020 Available from ir.canfite.com/press-releases/detail/917/can-fite-submits-investigational-new-drug-application-to-u-s-fda-for-covid-19-phase-ii-study. Regeneron`s COVID-19 outpatient study prospectively shows that the REGN-COV2 antibody cocktail significantly reduced virus levels and the need for additional medical care. Regeneron. 28 October 2020. Available from investor.regeneron.com/news-releases/news-release-details/regenerons-covid-19-outpatient-trial-prospectively-demonstrates. Since the beginning of the covid-19 pandemic in December 2019, many countries around the world have imposed containment measures to reduce the spread of the virus. Social isolation is known to have significant psychosis. COVID-19 Update: The FDA is extending emergency approval for Veklury (remdesivir) to all patients hospitalized for the treatment of COVID-19. U.S. Food and Drug Administration.
August 28, 2020 Available at www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized?utm_campaign=FDA%20Broadens%20Emergency%20Use%20Authorization%20for%20Veklury%20%28Remdesivir%29%20to%. WHO. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. WHO. Available at www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-(nsaids)-in-patients-with-covid-19. April 19, 2020; Accessed June 16, 2020. Enzychem Lifesciences announces FDA approval of the Phase 2 study of EC-18 for the prevention of acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia. Enzychem Life Sciences. 14.
August 2020 Available from www.enzychem.com/enzychem-lifesciences-announces-fda-acceptance-of-phase-2-study-of-ec-18-in-preventing-acute-respiratory-distress-syndrome-ards-due-to-covid-19-pneumonia/. [Guideline] NIH. Possible antiviral drugs for the treatment of COVID-19 in the assessment. Guidelines for the treatment of COVID-19. Available from www.covid19treatmentguidelines.nih.gov/antiviral-therapy/. June 11, 2020; Accessed June 16, 2020. Neuropsychological assessment provides important information about cognitive, behavioral and socio-emotional functions in medical, educational, legal and social contexts. During the COVID-19 pandemic of 2020, th. At the height of the COVID-19 pandemic, Thailand had almost exhausted its intensive care resources, especially beds and ventilators in intensive care units (ICUs). This led to the need to establish one. [Guideline] NIH. COVID-19 Treatment Guidelines Group Statement on the use of tocilizumab (and other interleukin-6 inhibitors) for the treatment of COVID-19.
Guidelines for the treatment of COVID-19. Available from www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-6-inhibitors/. 05 March 2021; Accessed March 12, 2021. The COVID-19 pandemic has affected how clinical trials are managed, both in existing portfolios and for rapidly developed COVID-19 trials. Sponsors or mandated bodies responsible for oversight. Live Updates: What drugs are in short supply due to COVID-19? GutRx. Available from www.goodrx.com/blog/covid-19-drug-shortages-updates/. Accessed April 15, 2020. Children and COVID-19: State-level data reporting. American Academy of Pediatrics. Available from services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/. June 17, 2021; Accessed June 25, 2021.
Romark is launching a new Phase 3 clinical trial of NT-300 for the treatment of COVID-19. Romark Pharmaceuticals. August 11, 2020 Available from www.romark.com/romark-initiates-new-phase-3-clinical-trial-of-nt-300-for-the-treatment-of-covid-19/. FSD Pharma begins a Phase 2 clinical trial evaluating FSD201 for the treatment of hospitalized patients with COVID-19. FSD Pharma Inc. September 28, 2020. Available from www.fsdpharma.com/news/fsd-pharma-begins-phase-2-clinical-trial-to-evaluate-fsd201-for-the-treatment-of-hospitalized-covid-19-patients/. Synthetic cannabinoid drug for COVID-19 approved for Phase 1 clinical trials. Forbes. 20. August 2020 Available from www.forbes.com/sites/emilyearlenbaugh/2020/08/20/synthetic-cannabinoid-drug-for-covid-19-approved-for-phase-1-clinical-trials/#7b9374223329.
CDC. Coronavirus disease 2019 (COVID-19) – Cases in the U.S. Centers for Disease Control and Prevention (CDC). Available from covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days. June 25, 2021; Accessed June 25, 2021. [Guideline] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines for the Treatment and Treatment of Patients with COVID-19. IDSA.
Available from www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/. 05 March 2021; Accessed March 12, 2021. The pandemic of this century has overwhelmed the health systems of the affected countries and all resources have been diverted to the coronavirus disease of 2019. For starters, coronavirus disease could have one in 2019. National Institutes of Health. NIH clinical trial of remdesivir for the treatment of COVID-19 begins. U.S. Department of Health and Human Services. Available from www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins. February 25, 2020; Accessed March 24, 2020.
COVID R&D Alliance launches drug trial from Amgen, UCB and Takeda. Reuters. November 30, 2020 Available from www.reuters.com/article/health-coronavirus-treatment-trial/covid-rd-alliance-launches-trial-of-amgen-ucb-takeda-drugs-idUSL1N2I31W4. VERU-111 suppresses key cytokines responsible for severe acute respiratory distress syndrome in COVID-19. Veru, Inc. August 04, 2020 Available from verupharma.com/news/veru-111-suppresses-key-cytokines-responsible-for-severe-acute-respiratory-distress-syndrome-in-covid-19/. The global health agenda is poorly defined as an analytical construct that complicates attempts by scientists and advocates to make claims about the status of the agenda of issues. .